No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
SLS250117P1000
- 0.23
- +0.03+15.00%
15min DelayClose Dec 26 16:00 ET
0.25High0.23Low
0.25Open0.20Pre Close215 Volume2.42K Open Interest1.00Strike Price5.35KTurnover266.76%IV23.76%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier22DDays to Expiry0.23Extrinsic Value100Contract SizeAmericanOptions Type-0.3654Delta0.5723Gamma4.04Leverage Ratio-0.0057Theta-0.0003Rho-1.48Eff Leverage0.0009Vega
Intraday
- 5D
- Daily
News
Promising Phase 2 Results and Strategic Potential Drive Buy Rating for SELLAS Life Sciences' SLS009
Express News | Sellas Life Sciences Group: Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating Interim Analysis
Express News | Sellas Life Sciences Group: Regal Independent Data Monitoring Committee to Perform Interim Analysis in Jan 2025
Express News | Sellas Life Sciences Triggers Interim Analysis in Phase 3 Regal Trial of Gps in Acute Myeloid Leukemia
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
SELLAS Reports Positive Survival Data From Mid-stage Trial of Its Leukemia Treatment